



EviTrade Announces the Appointment of Chris Brown as President

VANCOUVER, BC, Thursday February 21, 2019 – EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: EVAHF) (the “Company”) announces that it has appointed Mr. Chris Brown as President of the Company.

With over 20 years of practical business experience in both private and public enterprises, Mr. Brown has developed a keen eye for branding and effective corporate sales strategies. Most recently his business efforts have been focused on developing product lines, along with sales and marketing opportunities within the CBD (cannabidiol) marketplace.

Mr. Brown is also director and President of Western Agri Supply Solutions Corp. (“WASSC”) which was acquired by the Company in 2018 and continues as one of its wholly-owned subsidiaries.

WASSC is an agricultural supply company focused on sourcing and processing industrial hemp. Through utilization of a proprietary industrial-grade extraction system, WASSC is setting up to offer CBD based health and wellness products based on extracts from industrial hemp. Through initial testing, WASSC has predicted its production capacity to be in excess of 200 Kg of CBD isolate per month with an estimated market value currently of \$4,000 - \$8,000 per Kg.

Management is extremely pleased to have Mr. Brown join the executive team. His deep connections in the industrial hemp and CBD markets is expected to be an asset for realizing the potential of the Company’s personalized health system and projected operating plans for revenues.

Contact:

EVITRADE Health Systems Corp.
(formerly Auxellence Health Corporation)

Email info@evahealthsystems.com or ceo@auxellence.com

Website <http://www.evahealthsystems.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>

US OTC Markets (OTCQB): <http://www.otcmarkets.com/stock/EVAHF/news>

About EVITRADE Health (CSE: EVA, OTCQB: EVAHF)

EVITRADE Health Systems Corp. (formerly, Auxellence Health Corporation), is a technology company specializing in the Health and Life Sciences sector looking to deliver effective personalized health solutions with a higher degree of predictability and consistency.

The Company is focused on the following areas to help improve health: personalized medical care (including CBD usage monitoring and effects on the cardiovascular system), molecular biology, nutraceutical solutions and genetic tailoring.

Through its subsidiaries' focus on technologies involved in extracting and purifying CBD extracts for its personalized healthcare system, the Company may be the first to offer a complete quality assured vertically integrated "CBD Health System" for monitoring and recording the effects of CBD on your cardiovascular system.

Disclaimers

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>, and <http://www.otcmarkets.com/stock/EVAHF/filings>. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. The Company does not undertake to update this news release unless required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.